Dr Gregory Walker
PhD (Virology), 2022, University of New South Wales
B Biomedical Science (Hons), 2015, University of Newcastle
I am a Lecturer and virologist based at the Virology Research Laboratory (Prince of Wales Hospital Randwick), University of New South Wales. My research focuses on 1) viral detection and diagnostics, 2) genomic surveillance of viral epidemics, and 3) serological screening and characterisation of antibody-mediated immunity to viral infections. I am also an Associate Investigator within the Virology theme of the Environmental Determinants of Islet Autoimmunity (ENDIA) Study, following 1,500 mother-infant pairs with a first-degree relative with type 1 diabetes across Australia (ENDIA Study).
Research capabilities of myself and the lab include:
- Whole genome sequencing and genomic analysis of respiratory viruses (RSV, Influenzavirus, and SARS-CoV-2). Applications include molecular epidemiology and phylogenetics, monitoring viral evolution and transmission, identifying emerging variants, surveillance approaches such as wastewater-based detection, and assessing mutations associated with vaccine, monoclonal antibody and antiviral escape.
- Serological screening and immune profiling, including the development and application of assays (e.g. PhIP-Seq) to detect and and characterise virus-specific antibodies. This includes assessment of antibody binding, neutralising activity and cross-reactivity, cohort screening, and evaluation of immune responses to infection, vaccination and emerging viral variants.
- Isolation, culture, and phenotypic characterisation of viral isolates (including variants of SARS-CoV-2 under PC3 containment). These capabilities support investigation of viral replication, screening of novel therapeutic candidates, neutralisation sensitivity, antiviral susceptibility, and the functional significance of mutations identified through genomic surveillance.
I am interested in developing collaborative research programs and contributing virological expertise and laboratory capacity to investigator-led studies, translational projects and externally funded research.
Related news:
COVID not likely to trigger islet autoimmunity in Australian children
COVID-19 and Islet Autoimmunity
Rapid lab analysis informs global guidelines on COVID-19 vaccination and treatment
Pasteurisation inactivates COVID-19 virus in human milk new research finds
- Publications
- Media
- Grants
- Awards
- Research Activities
- Engagement
- Teaching and Supervision
NHMRC Investigator (EL1), 2024-2028. CIA, $662,040.
Characterising viruses that promote the development of type 1 diabetes. NHMRC European Partnership, 2024-2027. CID (CIA-Kim), $499,999
Epidemiology of Respiratory Syncytial Virus and other respiratory viruses. GSK Supported Study, 2023-2025. CIA, $95,654
Viral genetic determinants of respiratory syncytial virus (RSV) underlying clinical disease severity in pediatric infection. Thrasher Research Fund, 2023. CIA, US$25,000.
JDRF Australia (Breakthrough T1D) Career Support and Travel Grant 2025. $4000.
My Research Supervision
Completions
1x PhD student (School of Biomedical Sciences), 2022-2024, Genomic characterisation of influenza viruses
3x Honours students (2023-2025)
Current
1x PhD student (School of Biotechnology and Biomolecular Sciences), 2024- , Characterising the anti-viral antibody repertoire in children at risk of T1D in the ENDIA cohort
1x Honours student, 2026